New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas
| Autor: | Irina V. Poddubnaya, Vadim V. Ptushkin, Irena E. Belousova, L. G. Gorenkova, Kamil D. Kaplanov, A. E. Karamova, Alla M. Kovrigina, O. A. Kolomeitsev, T. S. Konstantinova, Muza M. Kokhan, Tatyana I. Pospelova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Современная онкология, Vol 22, Iss 2, Pp 79-81 (2020) |
| Druh dokumentu: | article |
| ISSN: | 1815-1434 1815-1442 18151434 |
| DOI: | 10.26442/18151434.2020.2.200205 |
| Popis: | Relevance. Cutaneous T-cell lymphomas (CTCL) are not common diseases which are associated with a decrease in quality of life. Currently available systemic therapy rarely provides a stable and long-termed response. In Russia, current CTCL therapy is a big issue due to the limited access to modern targeted therapy, an absence of a National CTCL registry, and the difficulties in morphological diagnosis of these rare diseases. Since June 17, 2019, a new indication of brentuximab vedotin as a new treatment option for patients with CD30+ CTCL after at least one line of previous systemic therapy was registered. Brentuximab vedotin is a conjugate of a CD30 directed monoclonal antibody and an antitumor agent. Brentuximab vedotin is a CD30-directed monoclonal antibody conjugated to an antitumor agent. Aim. To identify the unresolved issues of current clinical practice and to adapt available approaches to the treatment and diagnosis of CD30 + CTCL given new therapeutic opportunities. Results. The available approaches to the systemic CTCL therapy in Russia routine clinical practice have been discussed, the unresolved issues of therapy and diagnosis have been identified, the routing of patients with CD30 + CTCL in Russia has been discussed, the importance of CD30 testing has been established, the profiles of patients with CTCL for treatment with brentuximab vedotin have been determined. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|